Phase II Study of HMPL-004 in Subjects With Crohn's Disease
| Status: | Recruiting |
|---|---|
| Conditions: | Gastrointestinal, Crohns Disease |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | April 2006 |
| Contact: | Xiaowei Lu, MD |
| Email: | Xiaowei.Lu@OmnicareCR.com |
| Phone: | 973-325-5668 |
Double-blind, randomized, multicenter, placebo-controlled study The purpose of this study is
to evaluate the efficacy and safety of HMPL-004 in patients with active moderate Crohn's
Disease,compared with placebo.
Inclusion Criteria:
- Have active confirmed Crohn's Disease (confirmed radiographically, endoscopic, or
histologically), with a CDAI of 220-400 at baseline screen
Exclusion Criteria:
- They have received anti-TNF-α antibody within 3 months of starting study medication,
or cyclosporine, tacrolimus, thalidomide or mycophenolate mofetil within 2 months of
starting study medication
We found this trial at
1
site
Click here to add this to my saved trials
